APExBIO台灣代理商-BRAND/AGENCY/代理品牌-APExBio
台灣代理商-BRAND/AGENCY/代理品牌/APExBIO台灣代理商
APExBIO提供優質的胜肽和生物分析試劑，廣泛產品線如Protease、Chromatin/Epigenetics表觀遺傳學、MAPK Signal、DNA Damege/DNA repair、細胞凋亡、腫瘤生物學、Stem cell等研究領域， 還提供定制的服務，包括多肽合成，抗體的生產和檢測的發展。產品線DNA/RNA prep kit、Drug Screening panel、Bioactive peptides、Growth factors、Biotinylation Reagents、tag peptides、amino Acids、Growth factors等。APExBIO產品質量都伴隨著證書的分析，高效液相色譜，質譜，和HMNR數據。>>更多APExBio商品
抗發炎/抗腫瘤/小分子抑制劑
- Dexamethasone (DHAP) | CAS#50-02-2 貨號A2324
- Nintedanib (BIBF 1120) | CAS#656247-17-5貨號 A8252
- MS436 | CAS#1395084-25-9 貨號 B1012
- ( KRAS G12D 抑制劑) MRTX-1133 | CAS#2621928-55-8 貨號 B8761
- Erastin | CAS#571203-78-6 貨號B1524
- Nivolumab | CAS#946414-94-4 貨號B8222
- 磷酸氯喹 | Chloroquine diphosphate CAS#50-63-5 貨號A8628
- (S)-Crizotinib | CAS#877399-52-5;1374356-45-2 貨號A8802
- Oxaliplatin | CAS#61825-94-3 貨號A8648
- ORY-1001| CAS#1431326-61-2 貨號B5882
- Chidamide | CAS#743420-02-2 貨號B5916 apexbt
- RHPS4n | CAS#390362-78-4 貨號B6186 (DNA Damage/DNA Repair)
- SCR7 | CAS#1533426-72-0 貨號A8705
- 17-DMAG (Alvespimycin) HCl | CAS#467214-21-7 貨號A2213
- Cisplatin | CAS# 15663-27-1 貨號A8321
抗氧化及氧化自由基分析
- 白藜蘆醇 (Resveratrol)| CAS#501-36-0 貨號 A4182
- DNA Damage/DNA Repair系列產品
- 黃芪黃酮 (Astragalin)| CAS#480-10-4 貨號N1897
- 槲皮素 (Quercetin) | CAS#117-39-5 貨號N1841 (Antitumor agent)
- 没食子兒茶素GC; (-)-gallocatechin | CAS#3371-27-5 貨號 N2414
- (-)-表沒食子兒茶素沒食子酸酯 (EGCG) | CAS#989-51-5 貨號A2600
- 綠原酸 (Chlorogenic acid) 貨號 N1769
- 人參皂甙Rb1 Ginsenoside Rb1 CAS#41753-43-9 貨號 N1620
- 槲皮素 (Quercetin) | CAS#117-39-5 貨號N1841 (Antitumor agent)
- SRT2104 (GSK2245840)| CAS#1093403-33-8 貨號 A3821
- SRT1720 HCl | CAS#1001645-58-4 貨號 A4180
- 氫過氧化脂質 (LPO) 檢測試劑盒| Lipid Hydroperoxide (LPO) Assay Kit 貨號 K2265
- 一氧化氮（NO）測定試劑盒 | Colorimetric Nitric Oxide (NO) Assay Kit 貨號K2107
化學染色試劑
- 吉姆薩染色液（10X) | Giemsa Staining Solution (10X) 貨號K1181
- 瑞氏染色液 (Wright Staining Solution) | 貨號 K1182
- 阿爾新藍和核固紅染色試劑盒(pH2.5) | 貨號 K1188
- ALP/AKP鹼性磷酸酶顯色試劑盒 | 貨號 K4151
- 抗酒石酸酸性磷酸酶（TRAP）染色試劑盒 | 貨號 K2606
- 0.4% 台盼藍溶液 (0.4% Trypan Blue Solution) | 貨號 K1183
- 結晶紫染色液 (Crystal Violet Staining Solution) | 貨號 K1184
- 麗春紅S (Ponceau S) | 貨號 B7778
- InstaBlue快速型蛋白質染色劑 (5-15分) | 貨號B8226
- 活死菌染色試劑盒 | Live-Dead Bacterial Staining Kit 貨號K2239
- 阿爾新藍和核固紅染色試劑盒，pH2.5 | Alcian Blue & Nuclear Fast Red Staining Kit 貨號 K1188
- DAB辣根過氧化物酶顯色試劑盒| DAB Horseradish Peroxidase Color Development Kit 貨號 K4152
細胞凋亡/鐵死亡及細胞增殖試劑
- Annexin V-APC Reagent | 貨號 K2293
- 3x (DYKDDDDK) | CAS#402750-12-3貨號A6001
- Ac-YVAD-AFC | CAS#219137-85-6 貨號 A8956
- Z-IETD-FMK | CAS# 210344-98-2 APExBIO 貨號B3232
- Z-VAD-FMK | CAS# 187389-52-2 APExBIO 貨號 A1902
- 凋亡蛋白酶5 螢光活性分析 | Caspase-5 Fluorometric Assay Kit 貨號K2195
- 凋亡蛋白酶4 螢光活性分析| Caspase-4 Fluorometric Assay Kit 貨號 K2198
- 凋亡蛋白酶1螢光活性分析(YVAD-AFC) | Caspase-1 Fluorometric Assay Kit APExBIO貨號K2010
- A23187, free acid | CAS#52665-69-7 APExBIO貨號B6646 (Calcium Channel)
- Ferrostatin-1 (Fer-1) | CAS#347174-05-4 APExBIO貨號 A4371
- MTT細胞增殖檢測試劑盒 | MTT Cell Proliferation Assay Kit APExBIO貨號K2249
- WST-1水溶性四唑鹽 | CAS#150849-52-8 貨號 B8301
- VX-765 | CAS# 273404-37-8 貨號A8238
抗生素類化合物
- Daptomycin | CAS#103060-53-3 貨號A1206
- 雷帕黴菌（Rapamycin） | CAS#53123-88-9 貨號A8167
- 濕黴素(Hygromycin B) | CAS#31282-04-9 貨號A2515
- G-418 (80 S 核醣體延伸抑制劑) | CAS# 108321-42-2 貨號A2513
- Kanamycin Sulfate | CAS#25389-94-0 貨號A2516
- Bleomycin sulfate , BLENOXANE® | CAS# 9041-93-4 貨號 A8331
- Cycloheximide| CAS#66-81-9 貨號 A8244
- 紅黴素(Erythromycin) | CAS#114-07-8 貨號 B1939
- 頭孢噻肟（鈉鹽）(Cefotaxime (sodium salt)) | CAS#64485-93-4 貨號C4588
- 洛伐他汀 (Lovastatin) | CAS#75330-75-5 貨號 A4365
- Actinomycin D | 貨號 A4448
- Ampicillin trihydraten| CAS# 7177-48-2 貨號B1662
- 替比培南（Tebipenem） | CAS#161715-21-5 貨號 B4864
- Nitrocefin | 顯色頭孢菌素底物 CAS#41906-86-9 貨號 B6052
- 羧芐青黴素(Carbenicillin) | CAS# 4800-94-6 貨號A2511
- Bleomycin Sulfate | CAS# 9041-93-4 貨號A8331
- Nystatin (Fungicidin) | CAS#1400-61-9 貨號B1993
- 阿奇霉素 (Azithromycin) | CAS#83905-01-5 貨號B1398
- 泛艾霉素 (Pirarubicin) | CAS#72496-41-4 貨號B2295
- 衣黴素 (Tunicamycin) | CAS#11089-65-9 貨號B7417
- Gentamycin Sulfate | CAS#1405-41-0 貨號A2514
- 安比西林Ampicillin sodium | CAS# 69-52-3 貨號A2510
- 離子黴素鈣鹽 | Ionomycin calcium salt CAS#56092-82-1 貨號B5165
細胞活性及細胞代謝試劑
- Alamar Blue 細胞/細菌活力檢測試劑盒| Alamar Blue Cell Viability Assay Kit 貨號 K2234
- 孔雀石綠磷酸鹽測定試劑盒| Malachite Green Phosphate Assay Kit 貨號K2245
- 葡萄糖攝取呈色檢測試劑盒 (WST-8 Glucose Uptake Assay Kit) 貨號 K2303
- 磺胺多巴酚B（Sulforhodamine B ,SRB）細胞毒性測定 | 貨號K2273
- 細胞凋亡DNA ladder萃取試劑盒 | DNA Ladder Extraction Kit貨號K1629
- 2-脫氧-D-葡萄糖 (2-Deoxy-D-glucose) | CAS# 154-17-6 貨號B1027
- GSH 和 GSSG 檢測試劑盒 | GSH and GSSG Assay Kit 貨號K4630
- 2-NBDG葡萄糖攝取檢測試劑盒| 2-NBDG Glucose Uptake Assay Kit 貨號 K2212
- 中性紅血球增殖檢測試劑盒| Neutral Red Cell Proliferation Assay Kit 貨號 K2262
- X-Gal (β – 半乳糖苷酶底物)| β – Galactosidase substrate X-Gal CAS#7240-90-6 貨號A2539
生物活性化合物
- 植物血凝素 (Phytohaemagglutinin) | CAS# 9008-97-3貨號N2852
- (鐵螯合劑) Deferasirox Fe3+ chelate | CAS#554435-83-5 貨號A3355
- (脫氧膽酸鈉) Deoxycholic acid sodium salt | CAS# 302-95-4 貨號 C6885
- 12-O-Tiglylphorbol-13-isobutyrate CAS#92214-54-5 貨號N2061
- (PMA化合物)12-O-tetradecanoyl phorbol-13-acetate CAS#16561-29-8 貨號N2060
- Cellobiose CAS#HY-N2325 | 貨號B7879
- 脫氫表雄酮(Dehydroepiandrosterone (DHEA) | CAS# 53-43-0 貨號 B1375
- Gap 26 | CAS#197250-15-0 貨號A1044
- Gap 27 | CAS#198284-64-9 貨號A1045
- JNJ-26854165 (Serdemetan) | CAS# 881202-45-5 貨號A4204
- CA-074 Me | CAS# 147859-80-1 貨號A8239
- Talabostat mesylate | CAS# 150080-09-4 貨號B3941
- TAPI-1 | CAS#171235-71-5 貨號 B4686
- Filipin III | CAS#480-49-9 貨號B6034
- Papain 木瓜蛋白酶 | CAS#9001-73-4 貨號 B8354
- Poly(I:C) Toll-like receptor 3 (TLR3) agonist CAS#24939-03-5 貨號B5551
代謝酶/蛋白酶
- 阿魏酸 (Ferulic acid ) | CAS# 1135-24-6 貨號 N1878
- 人工甜味劑（Sucralose） | CAS#56038-13-2 貨號 B1840
- Laminin (925-933) | 層粘連蛋白 (925-933)CAS#110590-60-8 貨號A1023
誘發疾病模型產品
蛋白抑制劑/緩衝液成分
- MG-132 (Proteasome inhibitor) |貨號A2585
- PMSF (Serine proteinases inhibitor)| CAS#329-98-6 貨號 A2587
- TAK-242 TLR 4 信號抑制劑CAS#243984-11-4 貨號A3850
- 磷酸酶抑制酵素Cocktails，Phosphatase Inhibitor Cocktail 3 (100X inDMSO) | 貨號K1014
- 蛋白酶抑制劑混合物Cocktails | Protease Inhibitor Cocktail貨號K1007/SIGMA P8340
- 蛋白酶抑制劑混合物Cocktails | Protease Inhibitor Cocktail貨號K1011/SIGMA P9599
- 磷酸酶抑制酵素Cocktails | Phosphatase Inhibitor Cocktail 2 (100X in ddH2O) 貨號K1013
- 蛋白酶 K (Proteinase K) | CAS#39450-01-6 貨號K1037
- 亮肽素微生物(Microbial Leupeptin) | CAS#103476-89-7 貨號 A2570
- Tricine | CAS#5704-04-1 貨號B7780 (Proteases)
- Cycloheximide| CAS#66-81-9 貨號 A8244
各式螢光染劑
- JC-1 粒線體膜電位螢光探針 | CAS#3520-43-2 貨號A3516
- CY7染劑 (Cyanine 7) | CAS#943298-08-6貨號C8204
- CY3染劑 (Cyanine 3) | CAS#146368-13-0 貨號C8205
- CY5染劑 (Cyanine 5) | CAS#146368-11-8 貨號C8198
- 羅丹明B (Rhodamine B)| CAS#81-88-9 貨號A4705
- FITC-UEA-I | UEA I Lectin (FITC) 貨號C8599
- Mito-Tracker Red CMXRos | 貨號 B8810
抑制劑 (inhibitor) /抑制劑庫
- 酪胺酸激酶抑制劑庫 (DiscoveryProbe™ Tyrosine Kinase Inhibitor Library) 貨號 L1028
- iscoveryProbe™ FDA-approved Drug Library 貨號L1021
- DiscoveryProbe™ 臨床和 FDA 批准的藥物庫| FDA Clinical & FDA approved Drug Library貨號 L1052
- Nitrotetrazolium Blue chloride | CAS# 298-83-9 貨號B5943
- 細胞鬆弛素D (Cytochalasin D) | CAS#22144-77-0 貨號B6645
- 秋水仙鹼(Colchicine) | CAS#64-86-8 貨號 A3324
- 甲磺酸去鐵胺(Deferoxamine mesylate) | CAS#138-14-7 貨號B6068
- 乙醯氨基酚(acetaminophen/ paracetamol) | CAS# 103-90-2貨號 B3532
- Streptozocin | CAS#18883-66-4 APExBIO 貨號A4457
- Deoxycholic acid sodium salt | CAS# 302-95-4 貨號 C6885
- NSC 74859 ( S3I-201 Stat3 的選擇性抑制劑) | CAS#501919-59-1 貨號A8338
- HDAC組蛋白去乙醯化酶抑制劑 | JNJ-26481585 Potent HDAC inhibitor CAS#875320-29-9 貨號A4090
- Aprotinin牛胰蛋白酶抑制劑 | CAS#9087-70-1 貨號A2574
- EGTA| Calcium chelator CAS#67-42-5 貨號B7195
- Bromodomain Inhibitor, (+)-JQ1 | CAS# 1268524-70-4 貨號A1910
- MG 149 | CAS# 1243583-85-8 貨號B3276HAT inhibitor
- MG 149 (Tip60 HAT inhibitor) 選擇性抑制劑 | CAS# 1243583-85-8 貨號 B3276
- CHZ868 | Type II JAK2 inhibitor 貨號B5980
- MS023 (type I PRMTs inhibitor抑制劑) | CAS# 1831110-54-3 貨號 B6183
- 4′-bromo-Resveratrol (Sirt1 和 Sirt3 抑制劑) | CAS# 1224713-90-9 貨號 C3552
- MRTX-1133 | CAS#2621928-55-8 APExBIO貨號 B8761
- Rucaparib (AG-014699,PF-01367338) | CAS#459868-92-9 貨號A4156
- 奧拉帕尼(Olaparib (AZD2281, Ku-0059436)| PARP抑制劑CAS#763113-22-0 貨號 A4154
- NSC 74859 ( S3I-201 Stat3 的選擇性抑制劑) | CAS#501919-59-1 貨號A8338
- RGFP966 | CAS#1357389-11-7;1396841-57-8 貨號A8803
- EPZ-6438 | CAS#1403254-99-8 貨號A8221
- Romidepsin (FK228, depsipeptide)）| CAS#128517-07-7 貨號A8173
- 阿魏酸 (Ferulic acid ) | CAS# 1135-24-6 貨號 N1878
病毒純化及轉染試劑
- 肝素管柱 (HyperTrap Heparin HP Column) 貨號PC1009
- 病毒濃縮試劑盒 | Virus Concentration Kit 貨號K2706
- 聚凝胺 Polybrene (10 mg/mL) | 貨號K2701
- 抗病毒: 乙醯半胱氨酸(Acetylcysteine) | Antioxidant;mucolytic agent CAS#616-91-1 貨號A8356
其它商品
螢光冷光mRNA商品
- EZ Cap™ Firefly Luciferase mRNA 貨號 R1018
- ARCA EGFP mRNA | 貨號 R1001
- Cy5-UTP (Cyanine 5-UTP) | 貨號B8333
- 氨基分子螢光標誌Cy5.5 NHS ester (non-sulfonated) | 貨號A8103
- EZ Cap™ Reagent AG | Co-transcription capping reagent 貨號B8176
- EZ Cap™ Cy5 Firefly Luciferase mRNA (5-moUTP) 貨號R1010
- EZ Cap™ Cy5 EGFP mRNA (5-moUTP) 貨號 R1011
- Coelenterazine h | CAS#50909-86-9 貨號C3587
細胞外泌體商品
| 品項 | CAS# | #貨號 | 應用 |
| Romidepsin (FK228, depsipeptide) |
CAS#128517-07-7
|
貨號A8173 | HDAC1/HDAC2，強效和選擇性抑制劑 |
| Pirarubicin | CAS#72496-41-4 | 貨號B2295 | anthracycline anti-neoplastic doxorubicin |
| Tunicamycin | CAS# 15663-27-1 |
貨號A8321
|
高效、廣譜的化療藥物 |
| Azithromycin | CAS#83905-01-5 | 貨號A2213 | Hsp90 inhibitor |
| Bleomycin Sulfate |
CAS# 9041-93-4
|
貨號B1398 | Antibiotic by inhibiting protein synthesis |
| Nystatin (Fungicidin) | CAS#1400-61-9 | 貨號B1993 | antifungal antibiotic |
| Rapamycin | CAS#53123-88-9 | 貨號A8167 | Original antifungal antibiotic |
| Daptomycin | CAS#103060-53-3 | 貨號A1206 | Calcium-dependent antibiotic |
| 品項 | CAS# | #貨號 | 應用 |
| MG 149 (Tip60 HAT inhibitor) 選擇性抑制劑 | CAS# 1243583-85-8 | 貨號 B3276 | HAT inhibitor |
| 4′-bromo-Resveratrol | CAS# 1224713-90-9 | 貨號 C3552 | Sirt1 和 Sirt3 抑制劑 |
| MS023 | CAS# 1831110-54-3 | 貨號 B6183 | type I PRMTs inhibitor抑制劑 |
| CHZ868 | N/O | 貨號B5980 | Type II JAK2 inhibitor |
| Chidamide | CAS#743420-02-2 | 貨號B5916 | Novel HDAC inhibitor |
| RGFP966 | CAS#1357389-11-7/1396841-57-8 | 貨號A8803 | Specific HDAC3 inhibitor |
| EPZ-6438 | CAS#1403254-99-8 | 貨號A8221 | EZH2 inhibitor, potent and selective |
| Bromodomain Inhibitor, (+)-JQ1 | CAS# 1268524-70-4 | 貨號A1910 | BET bromodomain inhibitor |
| Catalog No. | Name | CAS | Purity | Short Summary |
| A1001 | Adrenomedullin (1-12), human | 98.99% | Vasodilator | |
| A1002 | Beta-Amyloid (1-11) | 190436-05-6 | 98.58% | Amyloidogenic peptide |
| A1003 | Amyloid β-Protein (1-15) | 183745-81-5 | 98.58% | Principal component of amyloid |
| A1004 | Amyloid Precursor C-Terminal Peptide | 92.28% | For beta amyloid generation | |
| A1005 | Beta-Sheet Breaker Peptide iAβ5 | 182912-74-9 | 98.17% | Peptide which can inhibit amyloidogenesis |
| A1006 | Angiotensin I (human, mouse, rat) | 484-42-4 | 98.99% | Precursor of angiotensin II |
| A1007 | Angiotensin 1/2 (1-9) | 34273-12-6 | 98.77% | Vasoconstrictor |
| A1008 | Anti-Inflammatory Peptide 1 | 118850-71-8 | 99.99% | PLA2 inhibitor |
| A1009 | ANP (1-11), rat | 95.92% | Vasodilator | |
| A1010 | Myelopeptide-2 (MP-2) | 98.98% | Peptide used for restoring human T lymphocytes | |
| A1011 | b-Casomorphin (1-3) | 72122-59-9 | 99.56% | Milk protein casein analog, have an opioid effect |
| A1012 | Dynorphin (2-17), amide, porcine | 99.94% | A modulator of pain response | |
| A1013 | Endomorphin-1 | 189388-22-5 | 98.79% | Agonist of μopioid receptors,highly potent and selective |
| A1014 | Beta-Lipotropin (1-10), porcine | 77875-68-4 | 99.17% | Morphine-like substance |
| A1015 | alpha-Endorphin | 59004-96-5 | 98.00% | Neurotransmitters |
| A1016 | Ac-Endothelin-1 (16-21), human | 98.49% | ETA/ETB agonist,vasoconstrictor | |
| A1018 | Platelet Membrane Glycoprotein IIB Peptide (296-306) | 98.92% | Inhibits platelet aggregation | |
| A1019 | Glucagon (19-29), human | 64790-15-4 | 95.54% | Potent Ca2+/Mg2+-ATPase inhibitor |
| A1020 | GnRH Associated Peptide (GAP) (1-13), human | 100111-07-7 | 99.41% | Inhibitor of prolactin secretion |
| A1021 | Epidermal Growth Factor Receptor Peptide (985-996) | 96249-43-3 | 98.41% | EGFR Peptide (985-996) |
| A1022 | GTP-Binding Protein Fragment, G alpha | 74.64% | Hydrolyzes GTP to GDP | |
| A1023 | Laminin (925-933) | 110590-60-8 | 99.93% | Extracellular matrix glycoprotein |
| A1024 | LEP (116-130) (mouse) | 258276-95-8 | 98.17% | An antiobesity hormone |
| A1025 | a-MSH, amide | 581-05-5 | 99.59% | Melanocyte-stimulating hormones |
| A1026 | β-Interleukin I (163-171), human | 106021-96-9 | 99.58% | T cell activator |
| A1027 | β-Interleukin II (44-56) | 99.37% | Cytokine,regulating WBC | |
| A1028 | Cadherin Peptide, avian | 127650-08-2 | 99.90% | Role in cell adhesion |
| A1029 | Fas C- Terminal Tripeptide | 189109-90-8 | 97.61% | AC-SER-LEU-VAL-OH |
| A1030 | Interleukin II (60-70) | 99.99% | Cytokine,regulating WBC | |
| A1031 | Myelin Basic Protein (68-82), guinea pig | 98474-59-0 | 99.06% | Myelin Basic Protein |
| A1032 | Adrenorphin | 88377-68-8 | 97.00% | Endogenous μ/κ opioid agonist,potent and selective |
| A1033 | [Ser25] Protein Kinase C (19-31) | 136795-05-6 | 99.80% | PKC substrate |
| A1034 | Acetyl Angiotensinogen (1-14), porcine | 66641-26-7 | 99.81% | Angiotensinogen precursor |
| A1035 | Papain Inhibitor | 70195-20-9 | 97.15% | Inhibitor of peptidase activity of Papain |
| A1036 | Thrombin Receptor Activator for Peptide 5 (TRAP-5) | 141685-53-2 | 98.07% | Thrombin Receptor Activator for Peptide 5 |
| A1037 | TRH Precursor Peptide | 98.91% | Thyrotropin Releasing Hormone Precursor Peptide | |
| A1040 | Myelin Basic Protein (87-99) | 118506-26-6 | 99.85% | Encephalitogenic peptide |
| A1041 | Angiotensin (1-7) | 51833-78-4 | 99.70% | Vasoconstriction peptide hormone |
| A1043 | Angiotensin III (human, mouse) | 13602-53-4 | 98.97% | Aldosterone stimulator |
| A1044 | Gap 26 | 197250-15-0 | 99.56% | Gap junction blocker peptide, mapping to connexin 43 residue 63-75 |
| A1045 | Gap 27 | 198284-64-9 | 97.64% | Selective gap junction blocker |
| A1046 | Dynamin inhibitory peptide | 251634-21-6 | 99.53% | Peptide inhibitor of GTPase dynamin |
| A1047 | Angiotensin 1/2 (1-5) | 58442-64-1 | 99.65% | Vasoconstrictor |
| A1048 | Angiotensin 1/2 (1-6) | 47896-63-9 | 99.85% | Vasoconstrictor |
| A1049 | Angiotensin 1/2 (5-7) | 98.36% | Vasoconstrictor | |
| A1050 | Angiotensin 1/2 (2-7) | 99.80% | Vasoconstrictor | |
| A1051 | alpha-1 antitrypsin fragment | 99.10% | Protease inhibitor | |
| A1052 | alpha-1 antitrypsin fragment 235-243 [Homo sapiens]/[Papio hamadryas]/[Cercopithecus aethiops] | 98.00% | Protease inhibitor | |
| A1053 | amyloid A protein fragment [Homo sapiens] | 99.77% | Apolipoproteins related to HDL in plasma | |
| A1056 | Angiotensin 1/2 + A (2 – 8) | 51833-76-2 | 99.56% | Vasoconstrictor |
| A1057 | coagulation factor II (thrombin) B chain fragment [Homo sapiens] | 99.68% | Trypsin-like serine protease | |
| A1058 | Prothrombin (474-477) [Mus musculus] | 99.61% | Role in coagulation cascade | |
| A1061 | Cytochrome c – pigeon (88-104) | 86579-06-8 | 98.58% | Triggers T Cell response |
| A1062 | Cytochrome c fragment (93-108) | 99.20% | Initiates apoptosis | |
| A1063 | Cytochrome P450 CYP1B1 (190-198) [Homo sapiens] | 98.32% | Sequence: H2N-FLDPRPLTV-OH | |
| A1066 | erbB-2 | 99.72% | Tyrosine kinase (TK) receptor | |
| A1067 | eukaryotic translation elongation factor 1 alpha 1 (EEF1A1) (387-394) [Multiple species] | 98.20% | Elongation factor-1 subunit | |
| A1068 | eukaryotic translation initiation factor 3 | 98.44% | Eukaryotic translation initiator | |
| A1069 | ferritin heavy chain fragment [Multiple species] | 99.67% | Ferritin heavy chain fragment | |
| A1070 | IgG light chain variable region [Homo sapiens]/IgM/kappa antibody [Mus musculus] | 99.79% | IgG light chain region | |
| A1071 | immunoglobulin light chain variable region fragment [Homo sapiens] | 99.82% | Immunoglobulin light chain fragment | |
| A1072 | immunoglobulin light chain variable region fragment [Homo sapiens]/[Mus musculus] | 97.50% | Immunoglobulin light chain fragment | |
| A1073 | Immunoglobulin M heavy chain (IGHM) fragment [Homo sapiens] | 99.36% | Immunoglobulin M heavy chain | |
| A1075 | Influenza A virus fragment | 97.61% | Leu-Lys-Phe-Ala-Phe-Ser-Met-Met | |
| A1077 | Lamin fragment | 99.57% | Lys-Ala-Gly-Gln-Val-Val-Thr-Ile-Trp | |
| A1078 | Large T antigen – rhesus polyomavirus 560-568 | 99.08% | Large T antigen | |
| A1079 | MAP kinase fragment [Multiple species] | 97.00% | Lys-Tyr-Ile-His-Ser-Ala-Asn-Val-Leu | |
| A1080 | matrix protein (3-15) [Zaire ebolavirus] | 98.14% | Viral envelope associated protein peptide | |
| A1081 | MHC class II antigen (45-57) [Homo sapiens] | 83.75% | Major histocompatibility complex | |
| A1082 | ovalbumin (324-338) [Gallus gallus]/[Coturnix coturnix] | 98.23% | Triggers immuno response | |
| A1083 | p53 tumor suppressor fragment | 99.00% | Regulates cell cycle | |
| A1084 | parathyroid hormone (7-34) [Homo sapiens]/[Macaca fascicularis] | 99.71% | Enhancer of blood calcium level | |
| A1085 | prostate apoptosis response protein PAR-4 (2-7) [Homo sapiens] | 99.46% | Transcriptional repressor | |
| A1086 | Rac GTPase fragment | 99.65% | Fragment of small signaling G proteins | |
| A1087 | Rhodopsin peptide | 99.88% | Pigment in retina photoreceptor cell;GPCR | |
| A1088 | Ribosomal protein L3 peptide (202-222) amide | 99.76% | HIV-1 TAR RNA-binding protein | |
| A1090 | signal transducer and activator of transcription 6 fragment | 99.79% | STAT6 transcription factor | |
| A1092 | survivin (baculoviral IAP repeat-containing protein 5) (21-28) | 98.07% | Cancer Biology Peptides | |
| A1093 | transferrin fragment | 99.69% | Transferrin fragment | |
| A1094 | tumor protein p53 binding protein fragment [Homo sapiens]/[Mus musculus] | 99.06% | P53 binding protein fragment | |
| A1096 | type II collagen fragment | 99.56% | Specific for cartilaginous tissues | |
| A1097 | ubiquitin specific protease 3 fragment | 96.99% | Deubiquitinates uH2A/uH2B | |
| A1098 | vitamin D binding protein precrusor (208-218) [Homo sapiens]/[Oryctolagus cuniculus] | 99.83% | vitamin D binding protein precrusor | |
| A1099 | vitamin D binding protein precursor (353-363) [Homo sapiens] | 99.52% | Highly polymorphic serum glycoprotein | |
| A1105 | BNP (1-32), human | 114471-18-0 | 98.00% | Brain natriuretic peptide |
| A1107 | Cdk2/Cyclin Inhibitory Peptide I | 99.88% | Cell division protein kinase 2 | |
| A1109 | Endostatin (84-114)-NH2 (JKC367) | 99.66% | Angiogenesis inhibitor | |
| A1111 | Endothelin-1 (1-15), amide, human | 98.00% | Vasoconstrictor agent | |
| A1112 | Nitric Oxide Synthase (599-613) Blocking Peptide, Bovine Endothelial Cell | 99.74% | Blocker of NO production | |
| A1114 | Parathyroid Hormone (1-34), bovine | 12583-68-5 | 99.84% | Enhancer of blood calcium level |
| A1115 | Peptide YY(3-36), PYY, human | 123583-37-9 | 96.92% | Y2R agonist |
| A1117 | PKA inhibitor fragment (6-22) amide | 121932-06-7 | 98.62% | PKA inhibitor |
| A1118 | S6 Kinase Substrate Peptide 32 | 98.28% | Measures the activity of kinases that phosphorylate ribosomal protein S6. | |
| A1121 | Melanocyte stimulating hormone release inhibiting factor | 2002-44-0 | 98.00% | MSH release-inhibiting factor |
| A1123 | Amyloid Beta-Peptide (12-28) (human) | 107015-83-8 | 99.46% | sequence H2N-VHHQKLVFFAEDVGSNK-OH |
| A1124 | Amyloid Beta-Peptide (1-40) (human) | 131438-79-4 | 98.43% | Amyloid precursor protein |
| A1129 | Parathyroid hormone (1-34) (human) | 52232-67-4 | 99.82% | Increases blood calcium level |
| A1131 | COG 133 | 514200-66-9 | 99.03% | ApoE mimetic peptide |
| A1132 | β-Pompilidotoxin | 216064-36-7 | 99.84% | Slows Na+ channel inactivation |
| A1133 | Epidermal growth factor receptor (994-1002) acetyl/amide | 98.50% | EGF-family receptor | |
| A1134 | Agouti-related Protein (AGRP) (25-82), human | 99.67% | Agouti-related peptide(25-82) | |
| A1136 | Fusion glycoprotein (92-106) [Human respiratory syncytial virus] | 98.42% | glycoprotein | |
| A1138 | Glycoprotein B (485-492) | 99.61% | Invovled in HSV viral cell entry | |
| A1140 | HBcAg [Hepatitis B virus] (18-27) | 99.74% | Indicator of active viral replication | |
| A1141 | hemagglutinin (332-340) [Influenza A virus] | 98.84% | Partial antigenic glycoprotein | |
| A1142 | hemagglutinin precursor (114-122) amide [Influenza A virus] | 99.70% | Partial antigenic glycoprotein | |
| A1143 | heparin cofactor II precursor (SERPIND1) fragment [Homo sapiens] | 98.14% | Thrombin inhibitor | |
| A1144 | heparin cofactor II precursor fragment [Homo sapiens] | 99.72% | Thrombin inhibitor | |
| A1146 | Histone-H2A-(107-122)-Ac-OH | 97.81% | Histone-H2A peptide | |
| A1147 | Luteinizing hormone releasing hormone human acetate salt (LHRH) | 33515-09-2 | 98.34% | acitivator of MMP-2 and MMP-9, selective |
| A1149 | YAP-TEAD Inhibitor 1 (Peptide 17) | 99.56% | ||
| A1169 | 10058-F4 | 403811-55-2 | 98.03% | C-Myc-Max dimerization inhibitor |
| A1173 | AG-18 | 118409-57-7 | 99.68% | EGFR/PDGFR inhibitor |
| A1174 | AMG-517 | 659730-32-2 | 96.97% | TRPV1 antagonist,potent and highly selective |
| A1185 | BMS-754807 | 1001350-96-4 | 99.53% | IGF-1R/InsR inhibitor,potent and selective |
| A1186 | AMG-208 | 1002304-34-8 | 98.00% | C-Met inhibitor,potent and highly selective |
| A1196 | SGX-523 | 1022150-57-7 | 99.73% | MET inibitor, highly selective, ATP-competitive |
| A1198 | Levetiracetam | 102767-28-2 | 98.00% | Antiepileptic drug |
| A1206 | Daptomycin | 103060-53-3 | 98.77% | Calcium-dependent antibiotic |
| A1229 | Lansoprazole | 103577-45-3 | 98.00% | H+,K+-ATPase inhibitor |
| A1266 | WYE-354 | 1062169-56-5 | 99.39% | MTOR inhibitor,potent,ATP-competitive and cell-permeable |
| A1267 | Adapalene | 106685-40-9 | 99.91% | RARβ and RARγ agonist |
| A1295 | Granisetron HCl | 107007-99-8 | 99.85% | 5-HT3 receptor antagonist |
| A1296 | Exemestane | 107868-30-4 | 98.00% | Steroidal aromatase inhibitor,selective and irreversible |
| A1302 | GSK1904529A | 1089283-49-7 | 98.55% | Selective IGF-1R/IR inhibitor |
| A1307 | Letrozole | 112809-51-5 | 99.90% | Non-steroidal aromatase inhibitor |
| A1313 | Gatifloxacin | 112811-59-3 | 99.70% | Fluoroquinolone antibiotic,inhibits bacterial TOPO II |
| A1334 | Mosapride Citrate | 112885-42-4 | 99.90% | 5-HT receptor agonist |
| A1337 | U0126-EtOH | 1173097-76-1 | 99.34% | MEK1/2 inhibitor |
| A1352 | Zoledronic Acid | 118072-93-8 | 98.00% | Potent nitrogen-containing bisphosphonates |
| A1366 | Rocuronium Bromide | 119302-91-9 | 98.00% | TGF-βR I kinase inhibitor |
| A1367 | AP26113 | 1197958-12-5 | 98.00% | Anaplastic lymphoma kinase (ALK) inhibitor |
| A1372 | AZD3514 | 1240299-33-5 | 98.00% | Androgen receptor downregulator |
| A1373 | Biapenem | 120410-24-4 | 98.00% | Highly broad spectrum antibiotic agent |
| A1379 | Nelarabine | 121032-29-9 | 98.44% | Prodrug of ara-G for T-LBL/T-ALL |
| A1379 | Nelarabine | 121032-29-9 | 98.44% | Prodrug of ara-G for T-LBL/T-ALL |
| A1379 | Nelarabine | 121032-29-9 | 98.44% | Prodrug of ara-G for T-LBL/T-ALL |
| A1379 | Nelarabine | 121032-29-9 | 98.44% | Prodrug of ara-G for T-LBL/T-ALL |
| A1387 | AZD5363 | 1143532-39-1 | 99.94% | AKT inhibitor,pyrrolopyrimidine derived |
| A1389 | WZ4002 | 1213269-23-8 | 98.89% | Mutant-selective EGFR inhibitor(L858R,T790M), irreversible and potent |
| A1393 | WZ8040 | 1214265-57-2 | 98.36% | EGFR T790M inhibitor,irreversible amd potent |
| A1402 | Gemcitabine HCl | 122111-03-9 | 99.92% | Inhibits DNA synthesis,deoxycytidine analog |
| A1404 | Rigosertib sodium salt | 1225497-78-8 | 98.79% | Plk1 inhibitor |
| A1412 | Clofarabine | 123318-82-1 | 99.41% | Antimetabolite,inhibit DNA polymerase and ribonucleotide reductase |
| A1413 | CEP-32496 | 1188910-76-0 | 98.27% | BRAF(V600E)inhibitor,highly potent |
| A1425 | Losartan Potassium (DuP 753) | 124750-99-8 | 99.87% | Angiotensin AT1 receptor antagonist |
| A1428 | Fulvestrant (ICI 182,780) | 129453-61-8 | 99.18% | Estrogen receptor antagonist, high affinity |
| A1435 | CP-945598 HCl | 686347-12-6 | 98.00% | CB1 antagonist,selective and high affinity |
| A1447 | Cilnidipine | 132203-70-4 | 99.94% | Blocker of Dual L- and N-type calcium channel |
| A1450 | Lidocaine | 137-58-6 | 99.92% | Anasthetic and class Ib antiarrhythmic agent |
| A1493 | ABT-751 (E7010) | 141430-65-1 | 99.38% | Inhibitor of microtubule polymerization,antimitotic |
| A1500 | 7-Methoxycoumarin-4-acetyl-P-L-G-L-β-(2,4-dinitrophenylamino)A-R amide | 140430-53-1 | 99.93% | Substrate of matrix metalloproteinases assay |
| A1501 | Mca-Pro-Leu-NH2 | 98.00% | Substrate of matrix metalloproteinases assay | |
| A1602 | Dexrazoxane HCl (ICRF-187, ADR-529) | 149003-01-0 | 99.85% | Topoisomerase II inhibitor,intracellular ion chelator,cardioprotective agent |
| A1605 | Dynasore | 304448-55-3 | 98.00% | Dynamin and GTPase inhibitor |
| A1606 | L-a-Hydroxyglutaric acid disodium salt | 63512-50-5 | 95.00% | salt form of L-α-Hydroxyglutaric acid |
| A1615 | GANT61 | 500579-04-4 | 99.50% | GLI antagonist |
| A1623 | Epothilone A | 152044-53-6 | 98.00% | Microtubule stabilizing macrolide |
| A1624 | Zaragozic Acid A | 142561-96-4 | 98.00% | rat liver squalene synthase inhibitor |
| A1630 | Epothilone B (EPO906, Patupilone) | 152044-54-7 | 99.72% | Microtubule stabilizing macrolide |
| A1632 | SB202190 (FHPI) | 152121-30-7 | 99.84% | P38 MAPK inhibitor |
| A1655 | GW2580 | 870483-87-7 | 99.69% | CFMS kinase/CSF-1R inhibitor,selective and ATP-competitive |
| A1659 | Dutasteride | 164656-23-9 | 99.46% | 5-alpha-reductase inhibitor |
| A1663 | PD98059 | 167869-21-8 | 99.25% | MEK inhibitor,selective and reversible |
| A1664 | Celecoxib | 169590-42-5 | 99.71% | Selective cyclooxygenase-2 (COX-2) inhibitor |
| A1670 | Enzastaurin (LY317615) | 170364-57-5 | 98.94% | PKC beta inhibitor,potent and selective |
| A1684 | Aprepitant | 170729-80-3 | 98.62% | Substance P (SP) inhibitor |
| A1709 | GW9508 | 885101-89-3 | 99.93% | FFA1/GPR40 agonist,potent and selective |
| A1718 | Posaconazole | 171228-49-2 | 99.47% | Sterol C14ɑ demethylase inhibitor |
| A1720 | Duvelisib (IPI-145, INK1197) | 1201438-56-3 | 99.55% | PI3K-δ/PI3K-γ inhibitor |
| A1723 | Roscovitine (Seliciclib,CYC202) | 186692-46-6 | 99.10% | CDK inhibitor,potent and selective |
| A1736 | PA-824 | 187235-37-6 | 99.62% | Anti-tuberculosis drug |
| A1745 | Galanthamine HBr | 1953-04-4 | 98.81% | Acetylcholinesterase inhibitor |
| A1748 | Ramelteon | 196597-26-9 | 99.89% | Agonist of melatonin receptor(M1-M2),highly selective |
| A1755 | Tenofovir Disoproxil Fumarate | 202138-50-9 | 98.61% | Antiretroviral agent( HIV-1 RT inhibitor) |
| A1765 | Vincristine sulfate | 2068-78-2 | 98.64% | Microtubule disrupter,antitumor agent |
| A1767 | Entecavir Hydrate | 209216-23-9 | 99.67% | Antiviral drug used in hepatitis B infection |
| A1769 | KU-0060648 | 881375-00-4 | 98.00% | Dual DNA-PK/PI3-K inhibitor, ATP-competitive |
| A1778 | Vatalanib (PTK787) 2HCl | 212141-51-0 | 99.95% | Tyrosine kinase receptor inhibitor |
| A1792 | PD184352 (CI-1040) | 212631-79-3 | 99.41% | Selective MEK inhibitor |
| A1794 | LY2835219 | 1231930-82-7 | 98.48% | CDK4/6 inhibitor,potent and selective |
| A1796 | Mianserin HCl | 21535-47-7 | 99.42% | 5-HT2 receptor antagonist |
| A1821 | Ki8751 | 228559-41-9 | 99.43% | VEGFR-2 inhibitor,potent and selective |
| A1832 | Doxorubicin (Adriamycin) HCl | 25316-40-9 | 99.64% | Antitumour antibiotic,inhibits TOPO II. |
| A1835 | Pelitinib (EKB-569) | 257933-82-7 | 98.49% | EGFR inhibitor,potent and irreversible |
| A1845 | Canertinib (CI-1033) | 267243-28-7 | 99.52% | HER family tyrosine kinase inhibitor |
| A1855 | Bumetanide | 28395-03-1 | 98.77% | NKCC cotransporter inhibitor |
| A1882 | Cediranib (AZD217) | 288383-20-0 | 99.82% | VEGFR inhibitor receptor,highly potent |
| A1888 | TRAM-34 | 289905-88-0 | 98.00% | KCa3.1 blocker,potent and highly selective |
| A1894 | SL-327 | 305350-87-2 | 99.80% | Selective MEK1/2 inhibitor |
| A1900 | PSI | 158442-41-2 | 97.64% | Proteasome inhibitor |
| A1901 | Q-VD-OPh hydrate | 1135695-98-5 | 98.32% | Cell-permeable, irreversible pan-caspase inhibitor |
| A1902 | Z-VAD-FMK | 187389-52-2 | 98.60% | Cell-permeable, irreversible pan-caspase inhibitor |
| A1903 | E 64d | 88321-09-9 | 98.14% | Cysteine protease inhibitor |
| A1904 | Boc-D-FMK | 187389-53-3,634911-80-1 | 98.00% | Pan-caspase inhibitor |
| A1905 | 3-Deazaneplanocin,DZNep | 102052-95-9 | 98.00% | S-adenosylhomocysteine and EZH2 inhibitor |
| A1906 | Decitabine (NSC127716, 5AZA-CdR) | 2353-33-5 | 99.77% | Deoxycytidine analog and cellular diifferentiation inducer |
| A1907 | 5-Azacytidine | 320-67-2 | 98.00% | DNA methyltransferase inhibitor. |
| A1908 | AMI-1 | 20324-87-2 | 99.49% | PRMT1 inhibitor |
| A1909 | BIX 01294 | 935693-62-2 | 98.38% | G9a and GLP inhibitor |
| A1910 | Bromodomain Inhibitor, (+)-JQ1 | 1268524-70-4 | 98.98% | BET bromodomain inhibitor |
| A1912 | Lomeguatrib | 192441-08-0 | 99.55% | MGMT inhibitor |
| A1913 | RG 108 | 48208-26-0 | 99.86% | DNA methyltransferase inhibitor |
| A1914 | UNC0638 | 1255580-76-7 | 98.66% | G9a/GLP HMTase inhibitor, potent and selective |
| A1915 | Zebularine | 3690-10-6 | 99.18% | DNA methylation inhibitor |
| A1920 | Z-DEVD-FMK | 210344-95-9 | 98.00% | Caspase-3 inhibitor |
| A1921 | Z-DQMD-FMK | 767287-99-0 | 98.00% | Caspase-3 inhibitor,cell-permeable |
| A1922 | Z-VDVAD-FMK | 210344-92-6 | 98.00% | Caspase-2 inhibitor |
| A1923 | Z-VEID-FMK | 98.41% | Caspase-6 inhibitor | |
| A1924 | Z-WEHD-FMK | 210345-00-9 | 98.00% | Caspase 5 inhibitor,potent,cell-permeable and irreversible |
| A1925 | Caspase-3/7 Inhibitor I | 220509-74-0 | 99.31% | Caspase-3/7 inhibitor |
| A1926 | CA 074 | 134448-10-5 | 98.07% | Cathepsin B inhibitor |
| A1930 | Apoptosis Inhibitor | 54135-60-3 | 99.70% | Associate with caspase-3 inhibition |
| A1931 | Pyronaridine Tetraphosphate | 76748-86-2 | 99.47% | Antimalarial agent |
| A1932 | (-)-Huperzine A | 102518-79-6 | 99.63% | NMDA receptor antagonist/AChE inhibitor |
| A1933 | Carfilzomib (PR-171) | 868540-17-4 | 99.76% | Proteasome inhibitor, epoxomicin analog |
| A1934 | Oprozomib (ONX-0912) | 935888-69-0 | 97.63% | Proteasome inhibitor |
| A1935 | 5-Aminovaleric acid hydrochloride | 660-88-8 | 98.00% | used for the synthesis of polymers |
| A1945 | BIBR 1532 | 321674-73-1 | 99.80% | Telomerase inhibitor,novel and selective |
| A1947 | MEK162 (ARRY-162, ARRY-438162) | 606143-89-9 | 98.17% | MEK1/2 inhibitor,potent and selective |
| A1952 | NSC 23766 | 1177865-17-6 | 98.21% | Selective inhibitor of Rac1-GEF interaction. |
| A1958 | Etomidate | 33125-97-2 | 99.84% | General anesthetic with GABA modulatory and GABA-mimetic actions |
| A1971 | Etoposide | 33419-42-0 | 99.56% | Topo II inhibitor |
| A1980 | SNS-032 (BMS-387032) | 345627-80-7 | 99.49% | CDK inhibitor |
| A1984 | Bendamustine HCl | 3543-75-7 | 99.74% | Cytostatic agent for non-Hodgkin lymphomas |
| A1986 | Nu 6027 | 220036-08-8 | 98.00% | ATR/CDK inhibitor, potent and selective |
| A1987 | Ki16425 | 355025-24-0 | 99.02% | LPA receptor antagonist |
| A2005 | Nutlin-3b | 675576-97-3 | 98.48% | MDM2/p53 inhibitor |
| A2024 | PD168393 | 194423-15-9 | 98.00% | EGFR inhibitor |
| A2025 | Plerixafor (AMD3100) | 110078-46-1 | 98.00% | CXCR4 chemokine receptor antagonist |
| A2033 | PQ 401 | 196868-63-0 | 98.00% | IGF1R inhibitor,potent and cell-permeable |
| A2036 | Doripenem Hydrate | 364622-82-2 | 99.43% | Injectable antibiotic,ultra-broad spectrum |
| A2065 | IC-87114 | 371242-69-2 | 98.00% | PI3Kδ inhibitor |
| A2067 | PI-103 | 371935-74-9 | 98.66% | Class I PI3K, mTOR and DNA-PK inhibitor |
| A2080 | PIK-75 | 372196-77-5 | 99.40% | Inhibitor of PI3K isoform p110α |
| A2097 | Ifosfamide | 3778-73-2 | 98.65% | Cytostatic agent |
| A2098 | PRX-08066 Maleic acid | 866206-55-5 | 98.00% | 5-HT2B receptor antagonist,potent and selective |
| A2133 | Saracatinib (AZD0530) | 379231-04-6 | 99.86% | Src/Abl inhibitor,potent and selective |
| A2149 | Bosutinib (SKI-606) | 380843-75-4 | 99.78% | Potent Abl/Src kinases |
| A2150 | Andarine | 401900-40-1 | 99.78% | Androgen receptor agonist |
| A2168 | Dovitinib (TKI-258, CHIR-258) | 405169-16-6 | 99.81% | Multitargeted RTK inhibitor |
| A2171 | Carboplatin | 41575-94-4 | 99.50% | Antitumor agent that forms platinum-DNA adducts. |
| A2173 | SC 144 | 895158-95-9 | 99.21% | Gp130 inhibitor |
| A2174 | Lenvatinib (E7080) | 417716-92-8 | 99.11% | VEGFR inhibitor |
| A2187 | Cladribine | 4291-63-8 | 98.01% | Apoptosis inducer in CLL cells |
| A2198 | Genistein | 446-72-0 | 99.24% | ER agonist |
| A2213 | 17-DMAG (Alvespimycin) HCl | 467214-21-7 | 99.22% | Hsp90 inhibitor |
| A2224 | Stattic | 19983-44-9 | 99.82% | STAT3 inhibitor,small-molecule and potent |
| A2249 | T0901317 | 293754-55-9 | 99.91% | Liver X receptor agonist,potent and selective |
| A2251 | Tivozanib (AV-951) | 475108-18-0 | 98.26% | VEGFR inhibitor,potent and selective |
| A2278 | NVP-AEW541 | 475489-16-8 | 98.00% | IGF-IR inhibitor, novel, potent and selective |
| A2306 | Ellagic acid | 476-66-4 | 98.39% | Casein kinase 2 (CK2) inhibitor |
| A2307 | PHA-665752 | 477575-56-7 | 98.00% | C-Met inhibitor,potent and ATP-competitive |
| A2308 | TAK-438 | 1260141-27-2 | 98.00% | Blocker of potassium-competitive acid |
| A2310 | SR9009 | 1379686-30-2 | 99.71% | REV-ERB-α/β Agonist |
| A2323 | TCS 359 | 301305-73-7 | 99.26% | Potent FLT3 inhibitor |
| A2324 | Dexamethasone (DHAP) | 50-02-2 | 99.95% | Glucocorticoidan; anti-inflammatory |
| A2343 | Cyclophosphamide | 50-18-0 | 98.00% | Nitrogen mustard alkylating agent and prodrug. |
| A2355 | Mercaptopurine (6-MP) | 50-44-2 | 99.72% | Purine synthesis inhibitor |
| A2402 | Floxuridine | 50-91-9 | 99.22% | Antineoplastic antimetabolite |
| A2415 | Acitretin | 55079-83-9 | 99.87% | Metabolite of etretinate |
| A2431 | Acarbose | 56180-94-0 | 98.00% | Alpha-glucosidase inhibitor |
| A2436 | Fluoxetine HCl | 56296-78-7 | 99.60% | Serotonin reuptake inhibitor,selective |
| A2451 | Epirubicin HCl | 56390-09-1 | 98.62% | Antibiotic antitumor agent |
| A2456 | Pamidronate Disodium | 57248-88-1 | 98.00% | Bisphosphonate antiresorptive agent & bone resorption inhibitor |
| A2477 | Tyrphostin AG 1296 | 146535-11-7 | 99.90% | PDGFR inhibitor,selective and ATP-competitive |
| A2486 | Malotilate | 59937-28-9 | 98.72% | Stimulates hepatocyte regeneration |
| A2487 | Odanacatib (MK-0822) | 603139-19-1 | 99.04% | Cathepsin K,potent and selective |
| A2489 | Leucovorin Calcium | 6035-45-6 | 98.00% | Derivative of folic acid |
| A2510 | Ampicillin sodium | 69-52-3 | 98.00% | β-lactam antibiotic |
| A2511 | Carbenicillin, Disodium Salt | 4800-94-6 | 98.00% | Inhibits the cell-wall synthesis,antibiotic |
| A2512 | Chloramphenicol | 56-75-7 | 99.52% | Inhibits translation(blocking peptidyl transferase) |
| A2513 | Geneticin, G-418 Sulfate | 108321-42-2 | 98.00% | Aminoglycosidic antibiotic |
| A2515 | Hygromycin B | 31282-04-9 | 98.00% | Suitable for mammalian cell selection |
| A2516 | Kanamycin Sulfate | 25389-94-0 | 98.00% | Water-soluble antibiotic |
| A2517 | Tetracycline Hydrochloride | 64-75-5 | 98.48% | Bacteriostatic antibiotics |
| A2521 | VE-821 | 1232410-49-9 | 98.03% | ATR kinase inhibitor |
| A2531 | Fluoroorotic Acid, Ultra Pure | 703-95-7 | 99.62% | 5-Fluoroorotic acid |
| A2539 | X-Gal | 7240-90-6 | 99.48% | Substrate for β-galactosidase,used in blue/white screening |
| A2548 | Carmofur | 61422-45-5 | 98.00% | Cytostatic derivative of fluorouracilm,antineoplatic agent |
| A2552 | Quercetin dihydrate | 6151-25-3 | 98.23% | PLA2 and PI 3-kinase inhibitor |
| A2559 | Altretamine | 645-05-6 | 99.13% | Antineoplastic agent |
| A2570 | Leupeptin, Microbial | 103476-89-7 | 98.00% | Inhibitor of serine and cysteine proteases |
| A2571 | Pepstatin A | 26305-03-3 | 98.96% | Aspartic proteinases inhibitor |
| A2573 | AEBSF.HCl | 30827-99-7 | 99.68% | Serine protease inhibitor |
| A2574 | Aprotinin | 9087-70-1 | 98.00% | Inhibitor of bovine pancreatic trypsin |
| A2575 | Bestatin | 58970-76-6 | 98.00% | Aminopeptidase inhibitor |
| A2576 | E-64 | 66701-25-5 | 98.00% | Cysteine protease inhibitor,irriversible |
| A2577 | Batimastat (BB-94) | 130370-60-4 | 98.32% | MMP inhibitor |
| A2578 | Clasto-Lactacystin β-lactone | 154226-60-5 | ≥95.00% | Proteasome inhibitor |
| A2580 | Elastase Inhibitor, SPCK | 65144-34-5 | 98.00% | HLE inhibitor |
| A2583 | Lactacystin (Synthetic) | 133343-34-7 | 98.00% | Proteasome inhibitor |
| A2585 | MG-132 | 133407-82-6 | 97.56% | Proteasome inhibitor, Cell permeable, reversible |
| A2586 | Nafamostat Mesylate(FUT-175) | 82956-11-4 | 99.79% | Serine protease inhibitor |
| A2587 | PMSF | 329-98-6 | 99.78% | Serine proteinases inhibitor, irreversible |
| A2588 | PPACK Dihydrochloride | 142036-63-3 | 99.10% | Thrombin inhibitor |
| A2597 | Brivanib (BMS-540215) | 649735-46-6 | 99.59% | VEGFR-2 inhibitor,ATP-competitive |
| A2600 | (-)-Epigallocatechin gallate (EGCG) | 989-51-5 | 99.12% | Antioxidant, antiangiogenic and antitumor agent |
| A2601 | Aclacinomycin A | 57576-44-0 | 98.00% | Topoisomerase I and II inhibitor |
| A2602 | Calpain Inhibitor I, ALLN | 110044-82-1 | 98.00% | Calpain I/II/ B/L inhibitor |
| A2603 | Calpain Inhibitor II, ALLM | 136632-32-1 | 98.00% | Calpain inhibitor |
| A2604 | Celastrol | 34157-83-0 | 98.67% | Antioxidant, anti-inflammatory and immunosuppressive agent |
| A2606 | Epoxomicin | 134381-21-8 | 97.92% | Proteasome inhibitor |
| A2610 | Fenbendazole | 43210-67-9 | 99.57% | For pinworm treatment in animals |
| A2612 | MG-115 | 133407-86-0 | 98.00% | Potent reversible proteasome inhibitor |
| A2614 | Bortezomib (PS-341) | 179324-69-7 | 99.89% | Proteasome Inhibitor |
| A2623 | VU 0364439 | 1246086-78-1 | 98.00% | Positive allosteric mGluR-4 modulator |
| A2633 | Brivanib Alaninate (BMS-582664) | 649735-63-7 | 98.00% | VEGFR2 inhibitor,ATP-competitive |
| A2664 | VX-661 | 1152311-62-0 | 99.88% | F508del CFTR corrector |
| A2673 | AG-1024 | 65678-07-1 | 98.00% | Selective IGF-1R inhibitor |
| A2678 | SU11274 | 658084-23-2 | ≥95.00% | C-Met inhibitor,potent and selective |
| A2681 | TGX-221 | 663619-89-4 | 98.91% | PI3Kβ inhibitor,potent,selective and ATP competitive |
| A2689 | Butein | 487-52-5 | 98.00% | Protein kinase inhibitor |
| A2700 | 10Panx | 955091-53-9 | 99.29% | Panx-1 mimetic inhibitor |
| A2701 | Scrambled 10Panx | 1315378-72-3 | 98.68% | Panx-1 mimetic inhibitory peptide, blocks pannexin-1 gap junctions |
| A2754 | TG100-115 | 677297-51-7 | 98.02% | PI3Kγ/PI3Kδ inhibitor |
| A2782 | Amonafide | 69408-81-7 | 98.00% | DNA intercalator,Topo II inhibitor |
| A2806 | BX-912 | 702674-56-4 | 95.55% | PDK1 inhibitor,potent and ATP-competitive |
| A2813 | Ivermectin | 70288-86-7 | 98.00% | NAChR/purinergic P2X4 receptor modulator |
| A2822 | AC480 (BMS-599626) | 714971-09-2 | 98.00% | HER1/2 inhibitor,selective and efficacious |
| A2838 | OSI-930 | 728033-96-3 | 99.58% | Inhibitor of Kit, KDR, Flt, CSF-1R, c-Raf and Lck |
| A2842 | Melatonin | 73-31-4 | 99.81% | Melatonin receptors agonist |
| A2845 | Omeprazole | 73590-58-6 | 97.37% | H+,K+-ATPase inhibitor |
| A2846 | OSU-03012 (AR-12) | 742112-33-0 | 99.43% | Potent PDK1 inhibitor |
| A2852 | Leflunomide | 75706-12-6 | 99.69% | AHR agonist,immunosuppressive agent |
| A2884 | Doxazosin Mesylate | 77883-43-3 | 99.82% | α1-adrenergic receptor antagonist |
| A2890 | Nepafenac | 78281-72-8 | 98.00% | COX-1 and COX-2 inhibitor |
| A2917 | Flumazenil | 78755-81-4 | 99.85% | Benzodiazepine antagonist |
| A2942 | Masitinib (AB1010) | 790299-79-5 | 99.60% | Tyrosine kinase inhibitor, potent and selective |
| A2949 | Linifanib (ABT-869) | 796967-16-3 | 99.62% | VEGFR/PDGFR inhibitor |
| A2960 | Loratadine | 79794-75-5 | 98.24% | Peripheral HH1R antagonist |
| A2974 | Foretinib (GSK1363089) | 849217-64-7 | 98.36% | VEGF and HGF receptor inhibitor |
| A2977 | Cabozantinib (XL184, BMS-907351) | 849217-68-1 | 98.60% | VEGFR2/Met/Ret/Kit/FLT//AXL inhibitor |
| A2986 | ADL5859 HCl | 850173-95-4 | 99.16% | δ-opioid receptor agonist,selective |
| A3001 | PCI-32765 (Ibrutinib) | 936563-96-1 | 99.39% | Bruton’s tyrosine kinase (BTK) inhibitor |
| A3002 | ABT-888 (Veliparib) | 912444-00-9 | 99.87% | Potent PARP inhibitor |
| A3003 | MDV3100 (Enzalutamide) | 915087-33-1 | 99.78% | Androgen receptor antagonist |
| A3004 | Vemurafenib (PLX4032, RG7204) | 918504-65-1 | 98.48% | BRAF kinase inhibitor |
| A3005 | CAL-101 (Idelalisib, GS-1101) | 870281-82-6 | 99.91% | PI3K inhibitor |
| A3006 | GDC-0068 (RG7440) | 1001264-89-6 | 99.06% | Pan-AKT inhibitor,highly selective |
| A3007 | ABT-263 (Navitoclax) | 923564-51-6 | 98.02% | Potent Bcl-2 family inhibitor, inhibits Bcl-2, Bcl-xL, and Bcl-w |
| A3008 | Y-27632 dihydrochloride | 146986-50-7;129830-38-2 | 99.08% | ROCK1 inhibitor |
| A3009 | Sorafenib | 284461-73-0 | 99.87% | Raf kinases and tyrosine kinases inhibitor |
| A3010 | MK-2206 dihydrochloride | 1032350-13-2 | 99.59% | Akt1/2/3 inhibitor |
| A3011 | CHIR-99021 (CT99021) | 252917-06-9 | 98.32% | GSK-3 inhibitor, Cell-permeable, ATP-competitive |
| A3012 | Ruxolitinib (INCB018424) | 941678-49-5 | 99.64% | JAK inhibitor |
| A3013 | PD0325901 | 391210-10-9 | 99.74% | MEK inhibitor |
| A3014 | BGJ398 | 872511-34-7 | 99.74% | FGFR inhibitor ,potent and selective |
| A3015 | BKM120 | 944396-07-0 | 98.01% | Inhibitor of pan-Class I PI3K |
| A3016 | PLX-4720 | 918505-84-7 | 98.70% | BRAF kinase inhibitor |
| A3017 | Dasatinib (BMS-354825) | 302962-49-8 | 98.09% | Src and BCR-Abl inhibitor |
| A3018 | Trametinib (GSK1120212) | 871700-17-3 | 98.98% | MEK1 and MEK2 inhibitor, potent and selective |
| A3019 | AT-406 (SM-406) | 1071992-99-8 | 98.00% | IAP inhibitor |
| A3021 | GDC-0449 (Vismodegib) | 879085-55-9 | 99.64% | Hedgehog antagonist,potent and selective |
| A3022 | Pazopanib (GW-786034) | 444731-52-6 | 98.81% | VEGFR/PDGFR/FGFR inhibitor |
| A3023 | P005091 | 882257-11-6 | 99.67% | Ubiquitin-specific protease 7 (USP7) inhibitor |
| A3100 | (+)-MK 801 | 70449-94-4 | 99.38% | Potent NMDA antagonist |
| A3104 | (E)-2-Decenoic acid | 334-49-6 | 98.00% | Fatty acid identified in royal jelly |
| A3108 | 17 alpha-propionate | 19608-29-8 | 98.00% | Androgen antagonist |
| A3111 | 1alpha, 25-Dihydroxy VD2-D6 | 216244-04-1 | 98.00% | Deuterated form of vitamin D |
| A3115 | 24, 25-Dihydroxy VD3 | 40013-87-4 | 98.00% | Vitamin D analogue |
| A3118 | 3,3′-Diindolylmethane | 1968-05-4 | 99.69% | Anticancer and antineoplastic agent |
| A3119 | 360A | 794458-56-3 | 98.00% | G-quadruplex structures inhibitor |
| A3120 | 360A iodide | 737763-37-0 | 98.56% | G-quadruplex structures inhibitor |
| A3122 | PI4KIII beta inhibitor 3 | 1245319-54-3 | 98.00% | PI4KIII beta inhibitor |
| A3123 | 4′-Demethylepipodophyllotoxin | 6559-91-7 | 99.32% | Anti-cancer drug |
| A3124 | 5-hydroxypyrazine-2-carboxylic acid | 34604-60-9 | 99.15% | Metabolite of pyrazinamide (PZA) |
| A3125 | 5-Iodotubercidin | 24386-93-4 | 98.34% | Adenosine kinase inhibitor,potent |
| A3126 | 5-R-Rivaroxaban | 865479-71-6 | 99.49% | Factor Xa (FXa) inhibitor |
| A3130 | A 438079 | 899507-36-9 | 98.00% | P2X7 receptor antagonist,competitive and selective |
| A3131 | A 438079 hydrochloride | 899431-18-6 | 99.59% | P2X7 receptor antagonist,competitive and selective |
| A3132 | A 77-01 | 607737-87-1 | 99.50% | Potent ALK5 inhibitor |
| A3133 | A 83-01 | 909910-43-6 | 99.24% | ALK-5 inhibitor |
| A3134 | A-317491 | 475205-49-3 | 98.53% | P2X3 and P2X2/3 receptor antagonist |
| A3135 | A-443654 | 552325-16-3 | 99.79% | Akt inhibitor,potent and selective |
| A3136 | A-740003 | 861393-28-4 | 98.24% | P2X7 receptor antagonist |
| A3138 | A-867744 | 1000279-69-5 | 98.00% | Allosteric Modulator |
| A3139 | Abacavir | 136470-78-5 | 99.89% | Inhibitor of HIV reverse transcriptase |
| A3142 | Acamprosate calcium | 77337-73-6 | 99.78% | GABA receptor agonist and modulator of glutamatergic systems |
| A3143 | Adarotene | 496868-77-0 | 99.24% | Apoptosis inducer/DNA damage agent |
| A3145 | Afatinib dimaleate | 850140-73-7 | 99.49% | EGFR inhibitor |
| A3146 | AGI-6780 | 1432660-47-3 | 98.63% | IDH2/R140Q mutation inhibitor |
| A3147 | AH 6809 | 33458-93-4 | 98.00% | EP and DP receptor antagonist |
| A3148 | AIM-100 | 873305-35-2 | 98.95% | Ack1 inhibitor |
| A3149 | AKT inhibitor VIII | 612847-09-3 | 99.73% | Allosteric Akt kinase inhibitor |
| A3151 | Alarelin Acetate | 79561-22-1 | 99.88% | Synthetic GnRH agonist |
| A3153 | Aliskiren | 173334-57-1 | 98.95% | Direct renin inhibitor |
| A3155 | ALK inhibitor 2 | 761438-38-4 | 98.00% | ALK inhibitor, novel and selective |
| A3156 | Alogliptin Benzoate | 850649-62-6 | 98.00% | DPP-4 inhibitor,selective and potent,antidiabetic drug |
| A3157 | Alosetron | 122852-42-0 | 98.00% | 5-HT3 receptor antagonist |
| A3159 | Alosetron Hydrochloride | 122852-69-1 | 98.91% | 5-HT3 receptor antagonist,potent and highly selective |
| A3162 | Alvimopan | 156053-89-3 | 99.67% | Mu-opioid receptors antagonist |
| A3163 | Alvimopan dihydrate | 170098-38-1 | 98.00% | μ-opioid receptor antagonist,peripherally acting |
| A3165 | ALW-II-41-27 | 1186206-79-0 | 97.45% | Eph receptor inhibitor |
| A3166 | AM095 | 1345614-59-6 | 98.14% | Potent LPA1 receptor antagonist |
| A3167 | AM-095 free base | 1228690-36-5 | 98.12% | Potent LPA1 receptor antagonist |
| A3169 | AM679 | 1206880-66-1 | 98.00% | FLAP inhibitor |
| A3170 | AM966 | 1228690-19-4 | 99.69% | LPA1 antagonist, oral active, high affinity, selective, |
| A3171 | Amadacycline | 389139-89-3 | 99.46% | Tetracycline antibiotic |
| A3173 | AMD-070 | 558447-26-0 | 98.00% | CXCR4 antagonist,potent and selective |
| A3174 | AMD-070 hydrochloride | 880549-30-4 | 98.00% | CXCR4 antagonist,potent and selective |
| A3176 | Ampalex | 154235-83-3 | 98.54% | Ampakine and nootropic |
| A3177 | AN-2690 | 174671-46-6 | 98.60% | Antifungal agent |
| A3178 | AN-2728 | 906673-24-3 | 99.33% | PDE4 inhibitor,anti-inflammatory compound |
| A3179 | Anamorelin | 249921-19-5 | 99.68% | Ghrelin receptor agonist, synthetic, orally active |
| A3182 | Anguizole | 442666-98-0 | 98.00% | Inhibitor of HCV replication |
| A3184 | AR-A014418 | 487021-52-3 | 98.34% | GSK3β inhibitor, ATP-competitive and selective |
| A3185 | AR-C155858 | 496791-37-8 | 99.52% | MCT1 and MCT2 inhibitor |
| A3188 | ARRY-520 R enantiomer | 885060-08-2 | 98.00% | KSP inhibitor |
| A3189 | AS 602801 | 848344-36-5 | 98.72% | Jun Kinase Inhibitor |
| A3190 | ASC-J9 | 52328-98-0 | 98.00% | AR degradation enhancer,antiumor agent |
| A3191 | Ascomycin(FK 520) | 104987-12-4 | 98.00% | Macrolide immunosuppressant,FK-520 analog |
| A3192 | Asenapine hydrochloride | 1412458-61-7 | 98.00% | Atypical antipsychotic |
| A3193 | ASP3026 | 1097917-15-1 | 99.38% | ALK inhibitor,potent and selective |
| A3194 | AST 487 | 630124-46-8 | 99.29% | RET kinase inhibitor |
| A3195 | Asunaprevir (BMS-650032) | 630420-16-5 | 99.80% | NS3 protease inhibitor |
| A3196 | AT-101 | 90141-22-3 | 98.00% | BH3-mimetic,gossypol enantiomer |
| A3196 | AT-101 | 90141-22-3 | 98.00% | BH3-mimetic,gossypol enantiomer |
| A3197 | AT7519 Hydrochloride | 902135-91-5 | 99.80% | Multi-CDK inhibitor |
| A3197 | AT7519 Hydrochloride | 902135-91-5 | 99.80% | Multi-CDK inhibitor |
| A3197 | AT7519 Hydrochloride | 902135-91-5 | 99.80% | Multi-CDK inhibitor |
| A3197 | AT7519 Hydrochloride | 902135-91-5 | 99.80% | Multi-CDK inhibitor |
| A3197 | AT7519 Hydrochloride | 902135-91-5 | 99.80% | Multi-CDK inhibitor |
| A3198 | AT7519 trifluoroacetate | 1431697-85-6 | 98.00% | CDK/cyclin inhibitor |
| A3198 | AT7519 trifluoroacetate | 1431697-85-6 | 98.00% | CDK/cyclin inhibitor |
| A3198 | AT7519 trifluoroacetate | 1431697-85-6 | 98.00% | CDK/cyclin inhibitor |
| A3198 | AT7519 trifluoroacetate | 1431697-85-6 | 98.00% | CDK/cyclin inhibitor |
| A3199 | AT7867 dihydrochloride | 1431697-86-7 | 98.00% | Akt1 and p70S6K/PKA inhibitor |
| A3199 | AT7867 dihydrochloride | 1431697-86-7 | 98.00% | Akt1 and p70S6K/PKA inhibitor |
| A3199 | AT7867 dihydrochloride | 1431697-86-7 | 98.00% | Akt1 and p70S6K/PKA inhibitor |
| A3199 | AT7867 dihydrochloride | 1431697-86-7 | 98.00% | Akt1 and p70S6K/PKA inhibitor |
| A3201 | Atrasentan hydrochloride | 195733-43-8 | 98.00% | Endothelin receptor antagonist |
| A3201 | Atrasentan hydrochloride | 195733-43-8 | 98.00% | Endothelin receptor antagonist |
| A3201 | Atrasentan hydrochloride | 195733-43-8 | 98.00% | Endothelin receptor antagonist |
| A3201 | Atrasentan hydrochloride | 195733-43-8 | 98.00% | Endothelin receptor antagonist |
| A3202 | Avermectin B1 | 71751-41-2 | 98.00% | Insecticide |
| A3203 | Avermectin B1a | 65195-55-3 | 90.00% | Antiparasitic agent |
| A3204 | Avermectin B1b | 65195-56-4 | 98.00% | mixture of avermectins |